BCRX Latest Press Releases

-- October 21, 2026 --

BioCryst to Report Third Quarter 2026 Financial Results on November 4 Globe Newswire 4:01 PM

BioCryst Announces U.S. FDA Approval of ORLADEYO 150 mg Oral Pellets for Adults and Adolescents with HAE Globe Newswire 7:00 AM

-- October 5, 2026 --

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth Globe Newswire 7:00 AM

-- September 1, 2026 --

BioCryst to Present at Upcoming Investor Conference Globe Newswire 7:00 AM

-- August 25, 2026 --

BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan Globe Newswire 7:01 AM

-- August 5, 2026 --

BioCryst Reports Second Quarter 2026 Financial Results Globe Newswire 7:00 AM

-- July 22, 2026 --

BioCryst to Report Second Quarter 2026 Financial Results on August 5 Globe Newswire 7:00 AM

-- July 15, 2026 --

BioCryst Appoints David W. Jenkins as Chief Scientific Officer Globe Newswire 7:00 AM

-- July 2, 2026 --

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- June 29, 2026 --

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility Globe Newswire 7:00 AM

-- June 12, 2026 --

BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting Globe Newswire 7:00 AM

-- June 9, 2026 --

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- May 27, 2026 --

BioCryst to Present New HAE Data from ORLADEYO (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes